Amended Statement of Ownership (sc 13g/a)
February 14 2020 - 6:03AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Schedule 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT TO RULES 13d-1 (b), (c) AND (d)
AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)
(Amendment No. 3)*
CymaBay Therapeutics,
Inc.
(Name of Issuer)
Common Stock, par value $0.0001
(Title of Class
of Securities)
23257D103
(CUSIP Number)
December 31, 2019
(Date of Event
Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which
this Schedule is filed:
¨ Rule
13d-1(b)
x Rule
13d-1(c)
¨ Rule
13d-1(d)
*The remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing
information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall
not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
(Continued on following pages)
Page 1 of 12
Exhibit Index on Page 11
CUSIP # 23257D103
|
Page 2 of 12
|
1
|
NAME OF REPORTING PERSONS Foresite Capital Fund III, L.P. (“FCF III”)
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨ (b) x
|
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH
|
5
|
SOLE VOTING POWER
1,504,710 shares, except that Foresite Capital Management III, LLC (“FCM III”), the general partner of FCF III, may be deemed to have sole power to vote these shares, and James Tananbaum (“Tananbaum”), the managing member of FCM III, may be deemed to have sole power to vote these shares.
|
6
|
SHARED VOTING POWER
See response to row 5.
|
7
|
SOLE DISPOSITIVE POWER
1,504,710 shares, except that FCM III, the general partner of FCF
III, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM III, may be deemed
to have sole power to dispose of these shares.
|
8
|
SHARED DISPOSITIVE POWER
See response to row 7.
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
1,504,710
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|
¨
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
|
2.2%*
|
12
|
TYPE OF REPORTING PERSON
|
PN
|
* As reported by the Issuer in its Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission on November 5, 2019, as of October 31, 2019, the total number of shares of Common
Stock outstanding was 68,701,043.
CUSIP # 23257D103
|
Page 3 of 12
|
1
|
NAME OF REPORTING PERSONS Foresite Capital Management III, LLC (“FCM III”)
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨
(b) x
|
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH
|
5
|
SOLE VOTING POWER
1,504,710 shares, all of which are directly owned by FCF III. FCM III, the general partner of FCF III, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM III, may be deemed to have sole power to vote these shares.
|
6
|
SHARED VOTING POWER
See response to row 5.
|
7
|
SOLE DISPOSITIVE POWER
1,504,710 shares, all of which are directly owned by FCF III. FCM III, the general partner of FCF III, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM III, may be deemed to have sole power to dispose of these shares.
|
8
|
SHARED DISPOSITIVE POWER
See response to row 7.
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
1,504,710
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|
¨
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
|
2.2%*
|
12
|
TYPE OF REPORTING PERSON
|
OO
|
* As reported by the Issuer in its Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission on November 5, 2019, as of October 31, 2019, the total number of shares of Common
Stock outstanding was 68,701,043.
CUSIP # 23257D103
|
Page 4 of 12
|
1
|
NAME OF REPORTING PERSONS Foresite Capital Fund IV, L.P. (“FCF IV”)
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨
(b) x
|
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH
|
5
|
SOLE VOTING POWER
2,315,016 shares, except that Foresite Capital Management IV, LLC (“FCM IV”), the general partner of FCF IV, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM IV, may be deemed to have sole power to vote these shares.
|
6
|
SHARED VOTING POWER
See response to row 5.
|
7
|
SOLE DISPOSITIVE POWER
2,315,016 shares, except that FCM IV, the general partner of FCF
IV, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM IV, may be deemed to
have sole power to dispose of these shares.
|
8
|
SHARED DISPOSITIVE POWER
See response to row 7.
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
2,315,016
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|
¨
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
|
3.4%*
|
12
|
TYPE OF REPORTING PERSON
|
PN
|
* As reported by the Issuer in its Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission on November 5, 2019, as of October 31, 2019, the total number of shares of Common
Stock outstanding was 68,701,043.
CUSIP # 23257D103
|
Page 5 of 12
|
1
|
NAME OF REPORTING PERSONS Foresite Capital Management IV, LLC (“FCM IV”)
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨
(b) x
|
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH
|
5
|
SOLE VOTING POWER
2,315,016 shares, all of which are directly owned by FCF IV. FCM IV, the general partner of FCF IV, may be deemed to have sole power to vote these shares, and Tananbaum, the managing member of FCM IV, may be deemed to have sole power to vote these shares.
|
6
|
SHARED VOTING POWER
See response to row 5.
|
7
|
SOLE DISPOSITIVE POWER
2,315,016 shares, all of which are directly owned by FCF IV. FCM IV, the general partner of FCF IV, may be deemed to have sole power to dispose of these shares, and Tananbaum, the managing member of FCM IV, may be deemed to have sole power to dispose of these shares.
|
8
|
SHARED DISPOSITIVE POWER
See response to row 7.
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
2,315,016
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|
¨
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
|
3.4%*
|
12
|
TYPE OF REPORTING PERSON
|
OO
|
* As reported by the Issuer in its Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission on November 5, 2019, as of October 31, 2019, the total number of shares of Common
Stock outstanding was 68,701,043.
CUSIP # 23257D103
|
Page 6 of 12
|
1
|
NAME OF REPORTING PERSONS James Tananbaum (“Tananbaum”)
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨
(b) x
|
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH
|
5
|
SOLE
VOTING POWER
3,819,726 shares, of which 1,504,710, are directly owned by FCF III and
2,315,016 are directly owned by FCF IV. Tananbaum is the managing member of FCM III, which is the general partner
of FCF III, and the managing member of FCM IV, which is the general partner of FCF IV. Tananbaum may be deemed to
have sole power to vote these shares.
|
6
|
SHARED VOTING POWER
See response to row 5.
|
7
|
SOLE DISPOSITIVE POWER
3,819,726 shares, of which 1,504,710, are directly owned by FCF III and
2,315,016 are directly owned by FCF IV. Tananbaum is the managing member of FCM III, which is the general partner of FCF III, and the managing member of FCM IV, which is the general partner of FCF IV. Tananbaum may be deemed to have sole power to dispose of these shares.
|
8
|
SHARED DISPOSITIVE POWER
See response to row 7.
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
3,819,726
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|
¨
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
|
5.6%*
|
12
|
TYPE OF REPORTING PERSON
|
IN
|
* As reported by the Issuer in its Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission on November 5, 2019, as of October 31, 2019, the total number of shares of Common
Stock outstanding was 68,701,043.
CUSIP # 23257D103
|
Page 7 of 12
|
ITEM 1(A).
|
NAME OF ISSUER
|
|
|
|
CymaBay Therapeutics, Inc. (the “Issuer”)
|
|
|
ITEM 1(B).
|
ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
|
|
|
|
7999 Gateway Blvd, Suite 130
|
|
Newark, CA 94560
|
|
|
ITEM 2(A).
|
NAME OF PERSONS FILING
|
|
|
|
This Schedule is filed by Foresite Capital Fund III, L.P., a Delaware limited partnership (“FCF III”), Foresite Capital Management III, LLC, a Delaware limited liability company (“FCM III”), Foresite Capital Fund IV, L.P., a Delaware limited partnership (“FCF IV”), Foresite Capital Management IV, LLC, a Delaware limited liability company (“FCM IV”), and James Tananbaum. The foregoing entities and individuals are collectively referred to as the “Reporting Persons.”
|
|
|
ITEM 2(B).
|
ADDRESS OF PRINCIPAL OFFICE
|
|
|
|
The address for each of the Reporting Persons is:
|
|
|
|
c/o Foresite Capital Management
|
|
600 Montgomery Street, Suite 4500
|
|
San Francisco, CA 94111
|
|
|
ITEM 2(C).
|
CITIZENSHIP
|
|
|
|
See Row 4 of cover page for each Reporting Person.
|
|
|
ITEM 2(D).
|
TITLE OF CLASS OF SECURITIES
|
|
|
|
Common Stock, par value $0.0001
|
|
|
ITEM 2(D)
|
CUSIP NUMBER
|
|
|
|
23257D103
|
|
|
ITEM 3.
|
If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
|
|
|
|
Not applicable.
|
|
|
ITEM 4.
|
OWNERSHIP
|
|
|
|
The following information with respect to the ownership of the Common Stock of the Issuer by the persons filing this Statement is provided as of December 31, 2019:
|
CUSIP # 23257D103
|
Page 8 of 12
|
|
(a)
|
Amount beneficially owned:
See Row 9 of cover page for each Reporting Person.
|
|
(b)
|
Percent of Class:
See Row 11 of cover page for each Reporting Person.
|
|
(c)
|
Number of shares as to which such person has:
|
|
(i)
|
Sole power to vote or to direct the vote:
See Row 5 of cover page for each Reporting Person.
|
|
(ii)
|
Shared power to vote or to direct the vote:
See Row 6 of cover page for each Reporting Person.
|
|
(iii)
|
Sole power to dispose or to direct the disposition
of:
See Row 7 of cover page for each Reporting Person.
|
|
(iv)
|
Shared power to dispose or to direct the disposition
of:
See Row 8 of cover page for each Reporting Person.
|
ITEM 5.
|
OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
|
|
|
|
Not applicable.
|
|
|
ITEM 6.
|
OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
|
|
|
|
Under certain circumstances set forth in the limited partnership agreements of FCF III and FCF IV and the limited liability company agreements of FCM III and FCM IV the partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from the sale of, shares of the Issuer directly or indirectly owned by each such entity of which they are a partner or member.
|
|
|
ITEM 7.
|
IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
|
|
|
|
Not applicable.
|
|
|
ITEM 8.
|
IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
|
|
|
|
Not applicable
|
|
|
ITEM 9.
|
NOTICE OF DISSOLUTION OF GROUP.
|
|
|
|
Not applicable
|
CUSIP # 23257D103
|
Page 9 of 12
|
|
|
ITEM 10.
|
CERTIFICATION.
|
|
|
|
By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
|
CUSIP # 23257D103
|
Page 10 of 12
|
SIGNATURES
After reasonable inquiry and to the best of my
knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 13, 2020
|
FORESITE CAPITAL FUND III, L.P.
|
|
|
|
|
By:
|
FORESITE CAPITAL MANAGEMENT III, LLC
|
|
Its:
|
General Partner
|
|
|
|
|
By:
|
/s/ James Tananbaum
|
|
Name:
|
James Tananbaum
|
|
Title:
|
Managing Member
|
|
|
|
|
FORESITE CAPITAL MANAGEMENT III, LLC
|
|
|
|
|
By:
|
/s/ James Tananbaum
|
|
Name:
|
James Tananbaum
|
|
Title:
|
Managing Member
|
|
|
|
|
FORESITE CAPITAL FUND IV, L.P.
|
|
|
|
|
By:
|
FORESITE CAPITAL MANAGEMENT IV, LLC
|
|
Its:
|
General Partner
|
|
|
|
|
By:
|
/s/ James Tananbaum
|
|
Name:
|
James Tananbaum
|
|
Title:
|
Managing Member
|
|
|
|
|
FORESITE CAPITAL MANAGEMENT IV, LLC
|
|
|
|
|
By:
|
/s/ James Tananbaum
|
|
Name:
|
James Tananbaum
|
|
Title:
|
Managing Member
|
|
|
|
|
JAMES TANANBAUM
|
|
|
|
|
By:
|
/s/ James Tananbaum
|
|
Name:
|
James Tananbaum
|
CUSIP # 23257D103
|
Page 11 of 12
|
EXHIBIT INDEX
Exhibit
|
|
Found on
Sequentially
Numbered Page
|
|
|
|
Exhibit A: Agreement of Joint Filing
|
|
12
|
CUSIP # 23257D103
|
Page 12 of 12
|
exhibit A
Agreement of Joint Filing
The Reporting Persons hereby
agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock of the Issuer shall be filed on behalf
of each of the Reporting Persons. Note that a copy of the applicable Agreement of Joint Filing is already on file with the appropriate
agencies.
Cymabay Therapeutics (NASDAQ:CBAY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cymabay Therapeutics (NASDAQ:CBAY)
Historical Stock Chart
From Apr 2023 to Apr 2024